急性護理綜合症檢測市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、目標、樣本類型、最終用戶、地區、競爭細分

全球急性護理綜合症檢測市場在2022 年達到28.9 億美元的估值，並預計在預測期內大幅成長，預計到2028 年年複合成長率(CAGR) 為5.56%，預計2028 年將達到40 億美元。2028. 急性護理綜合症檢測是醫療機構中使用的一種診斷方法，特別是在急診科和急診護理機構中，用於快速識別和診斷患者急性症狀或病症的根本原因。這種方法涉及同時測試多種病原體，包括病毒、細菌和其他微生物，這些病原體可能導致患者的症狀。目的是迅速縮小潛在原因的範圍並指導適當的治療決策。事實證明，在患者表現出由各種傳染源引起的症狀的情況下，急性護理綜合症檢測尤其有價值。它使醫療保健提供者能夠就患者護理、隔離方案和治療選擇做出及時且明智的決策。這種測試方法在疾病爆發或大流行期間變得尤其重要，有助於醫療保健系統有效管理和應對大量湧入的出現類似症狀的患者。

主要市場促進因素

市場概況
預測期	2024-2028
2022 年市場規模	28.9億美元
2028 年市場規模	40億美元
2023-2028 年年複合成長率	5.56%
成長最快的細分市場	呼吸系統疾病
最大的市場	亞太地區

1.傳染病爆發的增加促進了市場成長：

傳染病爆發的升級極大地推動了全球急性護理綜合症檢測市場的擴張。傳染病的爆發對快速、準確的診斷解決方案提出了更高的需求，而急性護理綜合症檢測可以有效解決這個問題。這種測試方法有助於在疫情爆發期間快速識別致病病原體。快速診斷可以及早發現並及時實施遏制策略，例如隔離感染者和執行感染控制措施。急性護理綜合症檢測透過對導致爆發的潛在病原體進行全面分析，簡化了患者管理，從而可以製定適當的護理計劃和治療。迅速辨識病原體有助於限制疫情在社區和醫療機構內的傳播。急性護理綜合症檢測在識別攜帶者、隔離病例和遏制進一步傳播方面發揮作用。

2. 對及時診斷的需求不斷成長推動成長：

對及時診斷的日益成長的需求在推動全球急性護理症候群檢測市場方面發揮關鍵作用。及時診斷對於各種醫療狀況至關重要，特別是在急診環境中，快速且準確的診斷可以顯著影響患者的治療結果。及時、準確的診斷對於急診和急診護理機構尤其重要。急性護理綜合症檢測可對潛在病原體進行全面評估，使醫療保健提供者能夠及時查明症狀原因並啟動適當的治療策略。急性護理綜合症測試平台旨在快速提供結果，通常在幾個小時內。在必須立即診斷以防止疾病進展和併發症的情況下，這種快速的周轉時間證明是至關重要的。及時診斷可以提高醫療保健提供者管理患者病情、促進患者分診、隔離方案和有針對性的干涉措施的效率。傳統的診斷方法可能會因實驗室處理時間和樣本運輸而出現延誤，而與此不同的是，急性護理症候群檢測可以降低此類延誤的風險，確保及時診斷和治療。透過這種方法進行快速診斷可以改善患者的治療效果，儘早開始適當的治療可以降低疾病的嚴重程度、死亡率和併發症。

3. 越來越多採用即時偵測推動成長：

即時護理 (POC) 檢測的廣泛採用是全球急性護理綜合症檢測市場成長的重要推動力。照護端測試是指在患者所在地或附近進行的診斷測試，有助於立即得出結果，並指導快速的臨床決策。急性護理綜合症檢測整合到 POC 平台後，可以快速識別導致急性症狀的病原體，從而採取更及時、更合適的干涉措施。 POC 測試無需將樣品運送到集中實驗室，從而縮短了結果的周轉時間。在急診環境等時間敏感性至關重要的環境中，POC 測試可加速適當治療的啟動。傳統的實驗室檢測通常需要將樣本送到中心實驗室，導致等待結果的時間延長。 POC 檢測消除了樣本運輸和處理延遲的需要，確保患者得到快速診斷。 POC 檢測有助於在照護端進行全面的患者護理，最大限度地減少患者在設施內移動進行檢測的必要性。事實證明，這對於行動不便的危重病患尤其有價值。 POC 測試透過減少額外測試、諮詢和程序的需求來最佳化醫療資源分配。這可以節省成本並提高醫療保健效率。在緊急情況下，POC 測試可以快速提供關鍵的診斷訊息，使醫療保健提供者能夠做出明智的決策並優先考慮患者護理。

主要市場挑戰

1.與其他診斷測試的競爭：

症候群測試與其他診斷測試（例如分子診斷和血清學診斷）競爭。這些測試可以提供有關綜合症根本原因的更準確資訊。分子診斷可以找出引起此綜合症的特定病原體，而血清學診斷可以檢測病原體抗體的存在。這些見解可以指導診斷和治療決策。醫療保健提供者可能習慣於採用他們已經熟悉的傳統診斷方法，這可能導致不願意採用更新的症候群檢測方法。具有悠久歷史和既定可靠性的診斷方法可能會受到醫療保健專業人員的青睞，這使得綜合症檢測很難獲得認可。

2. 品質控制和標準化：

品質控制和標準化為全球急性護理症候群檢測市場帶來了重大挑戰。確保不同症候群檢測平台和檢測結果一致且準確對於診斷結果的可靠性和可重複性至關重要。症候群測試平台可能採用不同的技術、化學物質和試劑，這可能導致檢測性能的變化。靈敏度、特異性和檢測極限的差異會影響結果的準確性和可靠性。症狀檢測可以在各種實驗室環境中進行，包括臨床實驗室、醫院和照護端設施。測試程序、設備和人員專業知識的實驗室間差異可能會影響結果的一致性。同時針對多種病原體的症候群檢測需要最大限度地減少不同目標之間的交叉反應或乾擾。交叉反應可能會產生假陽性或假陰性結果。

3. 與醫療保健系統整合：

將症候群檢測技術整合到現有的醫療保健系統和工作流程中是全球急性護理症候群檢測市場的一項重大挑戰。無縫整合對於最大限度地發揮這些技術的優勢和廣泛採用至關重要。症狀檢測平台需要與現有的醫療資訊系統、電子健康記錄（EHR）和實驗室資訊管理系統（LIMS）相容。確保順利的資料交換和互通性在技術上可能很複雜。症狀測試會產生大量資料，需要相關醫療保健專業人員進行安全管理、儲存和存取。建立強大的資料管理和連接解決方案至關重要。設計使用者友善的介面，使醫療保健提供者能夠在現有工作流程中輕鬆存取和解釋症狀測試結果，這本身就面臨著挑戰​​。使用者介面的設計必須優先考慮可用性和效率。醫療保健人員，包括臨床醫生、實驗室技術人員和 IT 人員，需要接受培訓才能有效使用和整合症候群檢測技術。培訓計劃必須全面且持續。引進新技術通常需要改變現有的臨床和實驗室工作流程。克服變革阻力並確保平穩過渡對於成功整合至關重要。

主要市場趨勢

1. 即時檢測 (POCT) 的興起：

即時護理檢測（POC​​T）的興起成為全球急性護理症候群檢測市場的重要趨勢。現場護理測試涉及在患者所在地或附近進行的診斷測試，提供快速結果，指導立即臨床決策。 POCT 使醫療保健提供者能夠快速診斷並啟動治療計劃，特別是在時間敏感性至關重要的急性護理環境中。急性護理綜合症檢測適用於 POCT 平台後，有助於及時識別導致急性症狀的病原體，從而採取更及時、更合適的干涉措施。在照護端進行症狀檢測無需將樣本送到集中實驗室，從而縮短了結果的周轉時間。這種速度對於管理緊急情況和疫情至關重要，因此迅速做出決定至關重要。照護端症候群測試使醫療保健提供者能夠在床邊做出明智的決定。即時結果指導隔離措施、治療選擇和病患管理策略，共同增強整體照護。在傳染病爆發等情況下，基於 POCT 的急性護理症候群檢測有助於快速識別病例並實施適當的控制措施以防止進一步傳播，從而有助於快速遏制。 POCT 無需不必要的轉運、重複檢測和延長住院時間，從而最佳化資源分配。這種效率在資源有限的急診護理場景中尤其重要。面對大型集會或災難應變等事件，即時症狀檢測可以快速篩檢傳染病，有助於快速識別和管理潛在的疫情。 POCT 在進入中心實驗室的機會有限的偏遠或服務欠缺地區尤其有利。照護端的急性護理綜合症檢測彌補了診斷差距，增強了即時疾病監測、新出現病原體的早期發現以及及時的公共衛生應對措施。

細分市場洞察

疾病類型見解

2022 年，呼吸系統疾病領域主導了急性護理綜合症檢測市場，預計在未來幾年將繼續擴張。呼吸系統疾病是全球主要死亡原因之一。根據世界衛生組織 (WHO) 統計，2019 年呼吸系統疾病導致約 410 萬人死亡。呼吸系統疾病往往表現迅速，給診斷和治療帶來了挑戰。症狀檢測對於確定這些疾病的根本原因並及時開始治療起著至關重要的作用。鑑於呼吸道疾病通常有常見的症狀，如咳嗽、發燒和呼吸急促，急性照護症候群檢測有助於區分各種呼吸道病原體並指導適當的治療策略。呼吸道疾病在公共衛生影響、快速傳播和廣泛後果方面的重要性凸顯了透過急診症候群檢測進行有效疫情管理和遏制的重要性。預計 2023 年至 2030 年該細分市場將經歷最高的年複合成長率 (CAGR)。

目標洞察

2022 年，細菌細分市場在急性護理症候群檢測市場中佔據主導地位，預計未來幾年將保持成長動能。細菌是在單一循環中包含遺傳訊息的簡單細胞，它們可以引起一系列影響人類和動物的感染。細菌感染可出現在身體的各部位，包括皮膚、腦部、肺部、血液等。細菌感染通常進展迅速，為診斷和治療帶來挑戰。急性護理綜合症檢測在確定細菌感染的根本原因、促進早期干涉方面發揮關鍵作用。鑑於細菌感染具有傳染性，及時診斷對於預防疾病傳播至關重要。憑藉其快速結果，症狀檢測已被證明可以有效改善患者的治療效果。

樣本洞察

2022 年，拭子細分市場主導了急性護理綜合症檢測市場，預計未來將維持其成長軌跡。鼻咽拭子在採集上呼吸道檢體特別有效，上呼吸道中常見各種呼吸道病原體，包括流感和冠狀病毒等病毒。鼻咽拭子可直接進入鼻咽部，鼻咽部通常是許多呼吸道病毒的初始感染部位。這種接近性提高了病原體檢測的靈敏度。

最終用戶洞察

2022年，醫院部門在急性護理綜合症檢測市場中佔據顯著地位，預計將繼續擴大。醫院是管理急性醫療狀況、緊急情況和疫情的主要場所。事實證明，在這些環境中，為了及時診斷和管理有緊急醫療需求的患者，症狀檢測尤其不可或缺。醫院容納不同的患者群體，並且經常處理大量患者，這使得醫院成為症候群檢測的關鍵。快速識別多種病原體對於患者護理和感染控制至關重要。醫院急診室會遇到大量湧入的急性病例，而症狀檢測可以簡化此類情況下的分流和決策，從而能夠及時進行干涉。

區域洞察

北美已成為全球急性護理症候群檢測市場的領導者。尤其是美國和加拿大，擁有先進且發達的醫療保健基礎設施，可促進創新診斷技術（包括急性護理綜合症檢測）的快速採用和整合。該地區是技術創新和醫療保健研究的中心，推動了尖端症候群檢測平台和解決方案的開發。

請隨時聯繫以獲取更多資訊或其他見解。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球急性照護症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型（呼吸道疾病、胃腸疾病、泌尿生殖系統疾病、熱帶疾病、其他）
  • 依目標（細菌、病毒、真菌、寄生蟲）
  • 依樣本類型（血液、尿液、生物液體、糞便、拭子、其他）
  • 按最終使用者（醫院、臨床和診斷實驗室、研究和學術機構、其他）
  • 按公司分類 (2022)
  • 按地區
• 市場地圖

第 6 章：北美急性護理症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型
  • 按目標
  • 依樣品類型
  • 按最終用戶
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 7 章：歐洲急性護理症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型
  • 按目標
  • 依樣品類型
  • 按最終用戶
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區急診症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型
  • 按目標
  • 依樣品類型
  • 按最終用戶
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美洲急性護理症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型
  • 按目標
  • 依樣品類型
  • 按最終用戶
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲急性護理症候群檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病類型
  • 按目標
  • 依樣品類型
  • 按最終用戶
  • 按國家/地區
• MEA：國家分析
  • 南非急診護理症候群檢測
  • 沙烏地阿拉伯急診症候群檢測
  • 阿拉伯聯合大公國急性護理症候群檢測

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• 商業概覽
• 公司概況
• 產品與服務
• 財務（上市公司）
• 最近的發展
• SWOT分析
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA (BioFire Diagnostics)
  • Danaher Corporation (Cepheid, Inc.)
  • DiaSorin SpA (Luminex Corporation)
  • Eurofins Scientific (Eurofins Viracor)
  • Karius
  • Laboratory Corporation of America Holdings.
  • QIAGEN NV
  • QuantuMDx Group Ltd.

第 16 章：策略建議

The Global Acute Care Syndromic Testing Market achieved a valuation of USD 2.89 Billion in 2022 and is poised for substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.56% through 2028 and expected to reach at USD 4.00 Billion in 2028. Acute Care Syndromic Testing serves as a diagnostic approach utilized in healthcare settings, particularly in emergency departments and acute care facilities, for swiftly identifying and diagnosing the underlying causes of acute symptoms or conditions in patients. This methodology involves simultaneously testing for multiple pathogens, including viruses, bacteria, and other microorganisms, that could be responsible for a patient's symptoms. The objective is to promptly narrow down potential causes and guide appropriate treatment decisions. Acute care syndromic testing proves particularly invaluable in scenarios where patients exhibit symptoms attributable to various infectious agents. It enables healthcare providers to make timely and well-informed decisions about patient care, isolation protocols, and treatment choices. This testing approach becomes especially critical during disease outbreaks or pandemics, aiding healthcare systems in effectively managing and responding to a significant influx of patients presenting similar symptoms.

However, it is important to note that the specific types of tests used in acute care syndromic testing may encompass molecular assays (such as polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (for detecting antibodies), and other diagnostic methods. The selection of tests depends on the suspected pathogens and the clinical context.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 2.89 Billion
Market Size 2028	USD 4.00 Billion
CAGR 2023-2028	5.56%
Fastest Growing Segment	Respiratory Disease
Largest Market	Asia Pacific

1. Rise in Infectious Disease Outbreaks Boosts Market Growth:

The escalation of infectious disease outbreaks significantly fuels the expansion of the global acute care syndromic testing market. Outbreaks of infectious diseases generate an elevated demand for rapid and accurate diagnostic solutions, which acute care syndromic testing effectively addresses. This testing approach facilitates the quick identification of the responsible pathogens during outbreaks. Speedy diagnosis enables early detection and the timely implementation of containment strategies, such as isolating infected individuals and enforcing infection control measures. Acute care syndromic testing streamlines patient management by offering a comprehensive analysis of potential pathogens driving an outbreak, which in turn allows for appropriate care planning and treatment. Swiftly identifying the causative agent aids in limiting the spread of the outbreak within the community and healthcare settings. Acute care syndromic testing plays a role in identifying carriers, isolating cases, and curbing further transmission.

2. Increasing Demand for Timely Diagnostics Drives Growth:

The growing need for timely diagnostics plays a pivotal role in propelling the global acute care syndromic testing market. Timely diagnostics hold vital importance across various medical conditions, particularly in acute care settings where rapid and precise diagnosis can significantly influence patient outcomes. Prompt and accurate diagnosis is especially crucial in emergency departments and acute care facilities. Acute care syndromic testing provides a comprehensive assessment of potential pathogens, enabling healthcare providers to promptly pinpoint the cause of symptoms and initiate suitable treatment strategies. Acute care syndromic testing platforms are designed to deliver swift results, often within a matter of hours. This rapid turnaround time proves vital in situations where immediate diagnosis is imperative to prevent disease progression and complications. Timely diagnostics enhance the efficiency of healthcare providers in managing patients' conditions, facilitating patient triage, isolation protocols, and targeted interventions. Unlike traditional diagnostic methods that can experience delays due to laboratory processing times and sample transportation, acute care syndromic testing mitigates the risk of such delays, ensuring timely diagnoses and treatments. Rapid diagnosis through this approach can lead to improved patient outcomes, with early initiation of appropriate therapies reducing the severity of illness, mortality rates, and complications.

3. Increased Adoption of Point-of-Care Testing Drives Growth:

The heightened adoption of point-of-care (POC) testing serves as a significant driver for the growth of the global acute care syndromic testing market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, facilitating immediate results that guide swift clinical decision-making. Acute care syndromic testing, when integrated into POC platforms, enables the rapid identification of pathogens responsible for acute symptoms, resulting in more timely and suitable interventions. POC testing eliminates the need to transport samples to centralized laboratories, reducing turnaround times for results. In environments like acute care settings where time sensitivity is paramount, POC testing accelerates the initiation of appropriate therapies. Traditional laboratory testing often entails sending samples to central labs, leading to extended waiting times for results. POC testing obviates the need for sample transportation and processing delays, ensuring that patients receive rapid diagnoses. POC testing facilitates comprehensive patient care at the point of care, minimizing the necessity for patients to move within a facility for testing. This proves especially valuable for critically ill patients with limited mobility. POC testing optimizes healthcare resource allocation by reducing the requirement for additional tests, consultations, and procedures. This can yield cost savings and enhance healthcare efficiency. During emergencies, POC testing offers crucial diagnostic information rapidly, empowering healthcare providers to make informed decisions and prioritize patient care.

Key Market Challenges

1. Competition from other Diagnostic Tests:

Syndromic testing contends with other diagnostic tests such as molecular diagnostics and serological diagnostics. These tests may provide more accurate information about the underlying cause of syndromes. Molecular diagnostics can pinpoint the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. These insights can guide diagnoses and treatment decisions. Healthcare providers may be accustomed to employing traditional diagnostic methods they are already familiar with, potentially leading to reluctance in adopting newer syndromic testing approaches. Diagnostic methods that have a long-standing history and established reliability may hold favor with healthcare professionals, making it challenging for syndromic testing to gain acceptance.

2. Quality Control and Standardization:

Quality control and standardization pose significant challenges in the global acute care syndromic testing market. Ensuring consistent and accurate results across different syndromic testing platforms and assays is essential for the reliability and reproducibility of diagnostic outcomes. Syndromic testing platforms may employ diverse technologies, chemistries, and reagents, which can lead to variability in assay performance. Variances in sensitivity, specificity, and limit of detection can impact result accuracy and reliability. Syndromic testing may be conducted in various laboratory settings, including clinical laboratories, hospitals, and point-of-care facilities. Inter-laboratory variability in testing procedures, equipment, and personnel expertise can affect result consistency. Syndromic testing assays targeting multiple pathogens simultaneously need to minimize cross-reactivity or interference between different targets. Cross-reactivity can yield false-positive or false-negative results.

3. Integration with Healthcare Systems:

Integrating syndromic testing technologies into existing healthcare systems and workflows is a significant challenge in the global acute care syndromic testing market. Seamless integration is crucial to maximize the benefits and widespread adoption of these technologies. Syndromic testing platforms need to be compatible with existing healthcare information systems, electronic health records (EHRs), and laboratory information management systems (LIMS). Ensuring smooth data exchange and interoperability can be technically complex. Syndromic testing generates substantial data that requires secure management, storage, and access by relevant healthcare professionals. Establishing robust data management and connectivity solutions is essential. Designing user-friendly interfaces that enable healthcare providers to easily access and interpret syndromic testing results within their existing workflow presents its own challenges. The design of user interfaces must prioritize usability and efficiency. Healthcare personnel, including clinicians, laboratory technicians, and IT staff, require training to effectively use and integrate syndromic testing technologies. Training programs must be comprehensive and ongoing. Introducing new technologies often necessitates changes to established clinical and laboratory workflows. Over coming resistance to change and ensuring a smooth transition are crucial for successful integration.

Key Market Trends

1. Rise of Point-of-Care Testing (POCT):

The rise of Point-of-Care Testing (POCT) emerges as a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing pertains to diagnostic testing conducted at or near the patient's location, delivering rapid results that guide immediate clinical decision-making. POCT empowers healthcare providers to swiftly diagnose and initiate treatment plans, particularly in acute care settings where time sensitivity is paramount. Acute care syndromic testing, when adapted for POCT platforms, facilitates the prompt identification of pathogens responsible for acute symptoms, resulting in more timely and suitable interventions. Syndromic testing at the point of care eliminates the need to send samples to centralized laboratories, thereby reducing turnaround times for results. This rapidity is crucial in managing acute conditions and outbreaks, where swift decisions are essential. Point-of-care syndromic testing enables healthcare providers to make well-informed decisions at the bedside. Immediate results guide isolation measures, treatment choices, and patient management strategies, collectively enhancing overall care. During situations like infectious disease outbreaks, POCT-based acute care syndromic testing contributes to rapid containment by swiftly identifying cases and implementing appropriate control measures to forestall further spread. POCT optimizes resource allocation by negating the need for unnecessary transfers, repeat tests, and prolonged hospital stays. This efficiency is particularly pertinent in acute care scenarios marked by resource constraints. In the face of events like large gatherings or disaster responses, point-of-care syndromic testing can offer rapid screening for infectious diseases, aiding in swift identification and management of potential outbreaks. POCT can be especially advantageous in remote or underserved regions with limited access to central laboratories. Acute care syndromic testing at the point of care bridges diagnostic gaps, enhancing real-time disease surveillance, early detection of emerging pathogens, and timely public health responses.

Segmental Insights

Disease Type Insights

In 2022, the Respiratory Diseases Segment dominated the Acute Care Syndromic Testing Market and is projected to continue its expansion in the upcoming years. Respiratory diseases are among the leading global causes of death. According to the World Health Organization (WHO), respiratory diseases accounted for an estimated 4.1 million deaths in 2019. Respiratory diseases often manifest rapidly, making diagnosis and treatment challenging. Syndromic testing plays a crucial role in identifying the root cause of these diseases and initiating treatment promptly. Given that respiratory diseases often share common symptoms such as cough, fever, and shortness of breath, acute care syndromic testing proves instrumental in distinguishing between various respiratory pathogens and guiding appropriate treatment strategies. The significance of respiratory diseases in terms of public health impact, rapid transmission, and widespread consequences underscores the importance of effective outbreak management and containment through acute care syndromic testing. This segment is anticipated to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Target Insights

In 2022, the Bacteria Segment took precedence in the Acute Care Syndromic Testing Market and is forecasted to maintain its growth momentum in the years ahead. Bacteria are simple cells containing genetic information in a singular loop, and they can cause a range of infections affecting both humans and animals. Bacterial infections can manifest in various body parts, including the skin, brain, lungs, blood, and others. Bacterial infections often progress rapidly, posing challenges for diagnosis and treatment. Acute care syndromic testing plays a pivotal role in identifying the underlying cause of bacterial infections, facilitating early intervention. Given that bacterial infections can be contagious, prompt diagnosis becomes essential to prevent disease transmission. With its rapid results, syndromic testing proves effective in enhancing patient outcomes.

Sample Insight

In 2022, the Swabs Segment dominated the Acute Care Syndromic Testing Market and is projected to sustain its growth trajectory in the future. Nasopharyngeal swabs are particularly efficient in collecting samples from the upper respiratory tract, where various respiratory pathogens, including viruses like influenza and coronaviruses, are commonly found. Nasopharyngeal swabs provide direct access to the nasopharynx, often the initial site of infection for many respiratory viruses. This proximity enhances the sensitivity of pathogen detection.

End-User Insight

In 2022, the Hospital Segment held a prominent position in the Acute Care Syndromic Testing Market and is expected to continue expanding. Hospitals constitute primary settings for managing acute medical conditions, emergencies, and outbreaks. Syndromic testing proves particularly indispensable in these environments for promptly diagnosing and managing patients with urgent healthcare needs. Hospitals accommodate a diverse patient population and often handle high patient volumes, making them pivotal for syndromic testing. Rapidly identifying a wide array of pathogens is critical for patient care and infection control. Hospital emergency departments encounter a significant influx of acute cases, and syndromic testing streamlines triage and decision-making in such situations, enabling timely interventions.

Regional Insights

North America has established itself as a frontrunner in the Global Acute Care Syndromic Testing Market. The United States and Canada, in particular, possess advanced and well-developed healthcare infrastructure that fosters the swift adoption and integration of innovative diagnostic technologies, including acute care syndromic testing. The region is a hub for technological innovation and healthcare research, driving the development of cutting-edge syndromic testing platforms and solutions.

Please feel free to reach out for further information or additional insights.

Key Market Players

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocartis NV
• bioMerieux SA (BioFire Diagnostics)
• Danaher Corporation (Cepheid, Inc.)
• DiaSorin S.p.A (Luminex Corporation)
• Eurofins Scientific (Eurofins Viracor)
• Hologic Inc.
• Laboratory Corporation of America Holdings.
• QIAGEN N.V.
• QuantuMDx Group Ltd

Report Scope:

In this report, the Global Acute Care Syndromic Testing Markets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Care Syndromic Testing Market, By Disease Type:

• Respiratory Diseases
• Gastrointestinal Diseases
• Genitourinary Diseases
• Tropical Diseases
• Others

Acute Care Syndromic Testing Market, By Target:

• Bacteria
• Fungi
• Viruses
• Parasites

Acute Care Syndromic Testing Market, By Sample Type:

• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Others

Acute Care Syndromic Testing Market, By End User:

• Hospitals
• Clinical & Diagnostics Laboratories
• Research & Academic Institutions
• Others

Global Acute Care Syndromic Testing Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Acute Care Syndromic Testing Market.

Available Customizations:

• Global Acute Care Syndromic Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Care Syndromic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others)
  • 5.2.2. By Target (Bacteria, Viruses, Fungi, Parasites)
  • 5.2.3. By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others)
  • 5.2.4. By End User (Hospitals, Clinical & Diagnostics Laboratories, Research & Academic Institutions, Others)
  • 5.2.5. By Company (2022)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Acute Care Syndromic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Target
  • 6.2.3. By Sample Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Care Syndromic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Target
      • 6.3.1.2.3. By Sample Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Acute Care Syndromic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Target
      • 6.3.2.2.3. By Sample Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Acute Care Syndromic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Target
      • 6.3.3.2.3. By Sample Type
      • 6.3.3.2.4. By End User

7. Europe Acute Care Syndromic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Target
  • 7.2.3. By Sample Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acute Care Syndromic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Target
      • 7.3.1.2.3. By Sample Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Acute Care Syndromic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Target
      • 7.3.2.2.3. By Sample Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Acute Care Syndromic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Target
      • 7.3.3.2.3. By Sample Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Acute Care Syndromic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Target
      • 7.3.4.2.3. By Sample Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Acute Care Syndromic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Target
      • 7.3.5.2.3. By Sample Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Acute Care Syndromic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Target
  • 8.2.3. By Sample Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Acute Care Syndromic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Target
      • 8.3.1.2.3. By Sample Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Acute Care Syndromic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Target
      • 8.3.2.2.3. By Sample Type
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Acute Care Syndromic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Target
      • 8.3.3.2.3. By Sample Type
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Acute Care Syndromic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Target
      • 8.3.4.2.3. By Sample Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Acute Care Syndromic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Target
      • 8.3.5.2.3. By Sample Type
      • 8.3.5.2.4. By End User

9. South America Acute Care Syndromic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Target
  • 9.2.3. By Sample Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acute Care Syndromic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Target
      • 9.3.1.2.3. By Sample Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Acute Care Syndromic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Target
      • 9.3.2.2.3. By Sample Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Acute Care Syndromic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Target
      • 9.3.3.2.3. By Sample Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Acute Care Syndromic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Target
  • 10.2.3. By Sample Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acute Care Syndromic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Target
      • 10.3.1.2.3. By Sample Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Acute Care Syndromic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Target
      • 10.3.2.2.3. By Sample Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Acute Care Syndromic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Target

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Abbott Laboratories
  • 15.6.2. Becton, Dickinson and Company
  • 15.6.3. Biocartis NV
  • 15.6.4. bioMerieux SA (BioFire Diagnostics)
  • 15.6.5. Danaher Corporation (Cepheid, Inc.)
  • 15.6.6. DiaSorin S.p.A (Luminex Corporation)
  • 15.6.7. Eurofins Scientific (Eurofins Viracor)
  • 15.6.8. Karius
  • 15.6.9. Laboratory Corporation of America Holdings.
  • 15.6.10. QIAGEN N.V.
  • 15.6.11. QuantuMDx Group Ltd.

16. Strategic Recommendations